Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 2/20 | 0.48 |
| ▸ | CES2 | O00748 | 3/20 | 0.47 |
| ▸ | CES1 | P23141 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 4/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30480694 | 1.00 | F2R (0.48) | F2RCES2CES1PKMMAOB | |
| SCHEMBL7363929 | 0.88 | F2R (0.47) | F2RCES2CES1PKMMAOB | |
| SCHEMBL29847023 | 0.83 | F2R (0.48) | F2RCES2CES1PKMMAOB | |
| SCHEMBL485712 | 0.83 | F2R (0.48) | F2RCES2CES1PKMMAOB | |
| SCHEMBL25270267 | 0.83 | CES2 (0.50) | F2RCES2CES1PKMALDH1A1 | |
| SCHEMBL111637 | 0.81 | KEAP1 (0.53) | F2RCES2CES1PKMALDH1A1 | |
| SCHEMBL4638742 | 0.79 | DGAT1 (0.55) | F2RCES2CES1PKMALDH1A1 | |
| SCHEMBL3711371 | 0.79 | F2R (0.38) | F2RCES2CES1PKMMAPT | |
| SCHEMBL108131 | 0.79 | CES2 (0.47) | F2RCES2CES1PKMMAOB | |
| SCHEMBL7981585 | 0.79 | F2R (0.51) | F2RCES2CES1PKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 378 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117924196-A | Novel IDH1 mutant inhibitor and application thereof | 陕西中医药大学 | 2024-04-26 | — | — | CN | claimed |
| CN-116003260-B | Method for preparing 1-naphthylamine compound from urea derivative and prediction model thereof | 广州国家实验室 | 2023-07-18 | — | — | CN | claimed |
| CN-114950159-B | Preparation method of aromatic polymer separation membrane based on super acid catalysis | 南京工业大学 | 2023-06-06 | — | — | CN | claimed |
| CN-116003260-A | Method for preparing 1-naphthylamine compound from urea derivative and prediction model thereof | 广州国家实验室 | 2023-04-25 | — | — | CN | claimed |
| CN-113880786-A | Synthesis method and antioxidant application of camphene aldehyde thiazole hydrazone derivative | 江西农业大学 | 2022-01-04 | — | — | CN | claimed |
| CN-110092724-B | Preparation method of N, N-dimethyl-1-naphthylamine compound | 湖南大学 | 2021-08-31 | — | — | CN | claimed |
| EP-4735449-A1 | TETRACYCLIC COMPOUNDS CONTAINING A FUSED INDOLE FOR TREATING APOL1-MEDIATED CHRONIC KIDNEY DISEASE | OmniAB, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4698530-A1 | NK3 MODULATORS AND USES THEREOF | Kallyope, Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| US-12459942-B2 | Inhibiting (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-12404274-B2 | Macrocycles as factor xia inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250263410-A1 | NK3 MODULATORS AND USES THEREOF | KALLYOPE, INC. | 2025-08-21 | — | — | US | disclosed |
| WO-2025096751-A1 | MACROCYCLIC INHIBITORS OF ATP CITRATE LYASE | ESPERION THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| US-12281114-B2 | NK3 modulators and uses thereof | KALLYOPE, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| EP-0551632-B1 | Process for the preparation of halogenoanthranilic acid | RIEDEL DE HAEN AG (DE) | 1996-06-26 | — | — | EP | disclosed |
| WO-1996003388-A1 | 1,2-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-02-08 | — | — | WO | disclosed |
| WO-1995021817-A1 | SUBSTITUTED SPIRO COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1995-08-17 | — | — | WO | disclosed |
| WO-1995011883-A1 | 1,2-DIARYLCYCLOPENTENYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1995-05-04 | — | — | WO | disclosed |
| US-5310746-A | Insecticides, miticides, nematocides | ROUSSEL UCLAF (FR) | 1994-05-10 | — | — | US | disclosed |
| WO-1993024463-A1 | SUBSTITUTED PYRAZOLINES AND THEIR USE AS PEST-CONTROL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1993-12-09 | — | — | WO | disclosed |
| EP-0551632-A2 | Process for the preparation of halogenoanthranilic acid | RIEDEL-DE HAEN AKTIENGESELLSCHAFT (DE) | 1993-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263410-A1 | NK3 MODULATORS AND USES THEREOF | TAC3, TACR3, TACR2 | F2R 656/4885CES2 4101/4885CES1 4144/4885 |
| US-12459942-B2 | Inhibiting (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | F2R 576/4885CES2 3003/4885CES1 1757/4885 |
| US-12404274-B2 | Macrocycles as factor xia inhibitors | TFPI, TFPI2, F11 | F2R 21/4885CES2 4485/4885CES1 2137/4885 |
| US-12281114-B2 | NK3 modulators and uses thereof | TAC3, TACR3, TACR2 | F2R 656/4885CES2 4101/4885CES1 4144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.